Dr. Dileep Kumar Puppala, MD

Dr. Puppala practices at Texas Multi-specialty Group in Houston, Texas.

Dr. Puppala's NPI, 1215989900, was assigned on May 17, 2006. Dr. Puppala graduated from Rangaraya Medical College NTR in 1994. Dr. Puppala's Texas license number on file is L4661.

Dr. Puppala's primary practice is Texas Multi-specialty Group, at 13219 Dotson Rd Ste 210 Suite 210, Houston, TX 77070. The practice phone is (281) 955-0338.

Dr. Puppala's primary practice is Texas Multi-specialty Group in Houston, Texas. Dr. Puppala is also affiliated with Memorial Hermann-Texas Medical Center. The medical group on file is Texas Multi-Specialty Group. Dmand AI also links Dr. Puppala to 4 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Puppala practices, 6 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Puppala's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Puppala is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Puppala's licenses on file in 2 states: Texas and New York.

Dmand AI lists acute sinusitis, asthma, bronchitis, chronic lung disease, chronic obstructive pulmonary disease (COPD), chronic respiratory failure, hypersomnia and pleural effusion among the conditions Dr. Puppala treats.

CMS data shows 55,772 Medicare services from Dr. Puppala across 25 procedure codes in 2024, for 909 Medicare patients. Medicare paid $1,092,007 for them.

CMS counts 909 Medicare patients who saw Dr. Puppala in 2024. The largest group is 65 to 74, with 411 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.83, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Puppala's median patient age at 68, with 49% women.

In 2024, Dr. Puppala wrote 6,423 Medicare Part D claims for 853 patients. 68% of them were for generic drugs. CMS names the drug for 6,184 of them, across 55 drugs with 11 or more claims each, at $2,532,562 in total drug cost. In 2023, CMS named 5,337 claims across 55 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Puppala for performance year 2024, reported as part of a group. Dr. Puppala accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links Dr. Puppala to 4 clinical trials, 4 of them phase 3 studies. 1 is still active or recruiting. Conditions studied include Asthma, Respiratory Hypersensitivity and Idiopathic Interstitial Pneumonias. GlaxoSmithKline sponsors the most, 2.

CMS Open Payments shows 1,470 general payments to Dr. Puppala from 70 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 67% of the total. GlaxoSmithKline, LLC. paid the most, $45,074.

Dr. Puppala graduated from Rangaraya Medical College NTR in 1994.

Dr. Puppala is in network with 23 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 15. Check the plan with the practice before a visit.